Key regions: Japan, India, Italy, Brazil, South Korea
The demand for Anti-Hypertensive Drugs in Uzbekistan is on the rise, driven by a growing prevalence of hypertension and an aging population.
Customer preferences: Patients in Uzbekistan prefer Anti-Hypertensive Drugs that are effective, affordable, and easily accessible. They tend to favor generic drugs over branded ones, as they are more cost-effective. Moreover, they prefer drugs that have minimal side effects and are easy to administer.
Trends in the market: The Anti-Hypertensive Drugs market in Uzbekistan is expected to grow at a steady pace in the coming years. The market is driven by factors such as an increase in the prevalence of hypertension, a growing aging population, and an increase in healthcare spending. Moreover, the government's efforts to improve healthcare infrastructure and increase access to healthcare services are expected to further boost the market growth.
Local special circumstances: The healthcare system in Uzbekistan is undergoing significant reforms, with a focus on improving the quality of healthcare services and increasing access to healthcare for all citizens. The government has implemented various policies to improve the healthcare system, such as increasing healthcare spending, building new hospitals and clinics, and improving the availability of medicines. These reforms are expected to have a positive impact on the Anti-Hypertensive Drugs market in Uzbekistan.
Underlying macroeconomic factors: Uzbekistan's economy has been growing steadily in recent years, driven by factors such as a growing manufacturing sector, increased investment in infrastructure, and a favorable business environment. The country's GDP is expected to continue to grow in the coming years, which is likely to have a positive impact on the Anti-Hypertensive Drugs market. Moreover, the government's efforts to diversify the economy and reduce its reliance on natural resources are expected to create new opportunities for businesses in the healthcare sector.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
